Focused On-demand Library for tRNA-splicing endonuclease subunit Sen54

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q7Z6J9

UPID:

SEN54_HUMAN

Alternative names:

SEN54 homolog; tRNA-intron endonuclease Sen54

Alternative UPACC:

Q7Z6J9; Q86WV3; Q86XE4; Q8N9H2

Background:

The tRNA-splicing endonuclease subunit Sen54, also known as SEN54 homolog, plays a crucial role in the maturation of tRNAs, a fundamental process for protein synthesis. It operates by cleaving pre-tRNA to remove introns, facilitating the correct assembly of tRNA molecules. This protein's involvement in mRNA processing links tRNA splicing to pre-mRNA 3'-end formation, highlighting its multifunctional role in RNA processing.

Therapeutic significance:

Sen54's association with Pontocerebellar hypoplasia types 2A, 4, and 5, diseases characterized by severe brain development issues, underscores its potential as a target for therapeutic intervention. Understanding the role of tRNA-splicing endonuclease subunit Sen54 could open doors to potential therapeutic strategies.